Malaysian palm oil rises on lower output
The benchmark palm oil contract for September delivery on the Bursa Malaysia Derivatives Exchange gained 47 ringgit, or 1.19%, to 4,012 ringgit ($949.36) a metric ton at the close. The contract fell 2.57% this week. The Bursa Malaysia Derivatives Exchange palm oil contract will be closed on Friday for a public holiday.
Crude palm oil futures traded higher on the expectation that production and export would remain bullish in the coming weeks, said David Ng, a proprietary trader at Kuala Lumpur-based trading firm Iceberg X Sdn Bhd.
'We see production pace slowing down and robust demand going forward,' he added. The Malaysian Palm Oil Board is expected to release its June supply and demand data on July 10.
Dalian's most-active soyoil contract rose 0.58%, while its palm oil contract added 0.43%. Soyoil prices on the Chicago Board of Trade were down 0.06%.
Palm oil tracks the price movements of rival edible oils, as it competes for a share of the global vegetable oils market. Oil prices were steady after erasing earlier gains as investors remained cautious about the Iran-Israel ceasefire, while also shifting focus to market fundamentals. Stronger crude oil futures make palm a more attractive option for biodiesel feedstock.
The ringgit, palm's currency of trade, strengthened 0.21% against the dollar, making the commodity more expensive for buyers holding foreign currencies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
5 hours ago
- Business Recorder
PTA Global Holding replaces AsiaPak, Montage as acquirer of Lotte Chemical Pakistan
PTA Global Holding Limited, a UAE-based company, has replaced AsiaPak Investments Limited and Montage Oil DMCC as the new acquirer in the planned acquisition of a 75.01% stake in Lotte Chemical Pakistan Limited. Arif Habib Limited, manager to the offer, disclosed the development in its notice to the Pakistan Stock Exchange (PSX) on Monday. AHL announced the change in acquirer, resulting from a revised capital ownership structure, through an addendum submitted to the bourse. 'We, Arif Habib Limited would like to inform, vide this addendum to the Public Announcement of Intention, that due to a change in the capital ownership structure of the acquirers, a new foreign entity i.e. PTA Global Holding Limited will replace AsiaPak Investments Limited and Montage Oil DMCC as the acquirer for the acquisition of up to 1,135,860,105 of the ordinary shares (75.01%) of Lotte Chemical Pakistan Limited with Liberty Daharki Power Limited and Daewoo Pakistan Express Bus Service Limited acting in concert,' AHL said in its notice PTA Global Holding Limited is incorporated in the UAE and is directly owned by Asiapak Investments Limited and Montage Oil DMCC with equal stake in the shareholding. 'It is intended that PTA Global Holding Limited will only hold Asiapak Investments Limited and Montage Oil DMCC's interest in LCPL,' read the notice. Earlier in February, the Board of Directors of Lotte Chemical Corporation (LCC Korea), the majority shareholder of Lotte Chemical Pakistan Limited entered into a Share Purchase Agreement to sell the entire stake in the Pakistani subsidiary to AsiaPak Investments Limited and Montage Oil DMCC. Following this, the Competition Commission of Pakistan (CCP,) in May, approved the acquisition. AsiaPak Investments Limited is a private investment company incorporated in the British Virgin Islands, with investments in infrastructure, energy, logistics, and technology. Montage Oil DMCC, based in the UAE, is engaged in the global trade of oil and petrochemicals.
Express Tribune
6 hours ago
- Express Tribune
Isomorphic Labs, Google-backed, to launch human trials for AI-designed drugs
Alphabet's drug discovery arm, Isomorphic Labs, is preparing to enter a new chapter in its ambitious efforts to reshape medicine through artificial intelligence, with its first human clinical trials now on the horizon. Colin Murdoch, the company's president and also Google DeepMind's chief business officer, confirmed to Fortune that trials for AI-designed drugs could begin in the near future. 'We're staffing up now. We're getting very close,' he said during an interview in Paris. The London-based firm, spun out of DeepMind in 2021, was established off the back of AlphaFold, the AI system that stunned scientists by predicting protein structures with remarkable accuracy. That success laid the foundation for a broader mission: to use AI to design new drugs faster, cheaper and with a higher chance of clinical success. 'There are people sitting in our office in King's Cross, London, working, and collaborating with AI to design drugs for cancer,' Murdoch said. 'That's happening right now.' The company was born from one of DeepMind's most celebrated breakthroughs: AlphaFold, an AI system capable of predicting protein structures with a high level of accuracy. — FORTUNE (@FortuneMagazine) July 6, 2025 After several years of building infrastructure and refining its approach, Isomorphic is now transitioning from early-stage discovery into clinical development. According to Murdoch, 'The next big milestone is actually going out to clinical trials, starting to put these things into human beings.' AlphaFold's evolution from predicting single protein structures to modelling interactions between proteins, DNA and drug molecules has proven critical to that progress. It has enabled researchers to approach drug design with greater precision, a shift Murdoch believes will help unlock an era of AI-driven breakthroughs in medicine. 'This was the inspiration for Isomorphic Labs,' he said. 'It really demonstrates that we could do something very foundational in AI that could help unlock drug discovery.' Isomorphic Labs is reimagining drug discovery with the power of AI, and we're scaling our ML team to support the rapid growth of our best-in-class AI models. Heading to ICML and want to find out more? Register to connect with some of our ML team at ICML between 13-19 July:… — Isomorphic Labs (@IsomorphicLabs) July 3, 2025 The company's ambitions are matched by growing financial and industry support. In April 2025, Isomorphic raised $600 million in its first-ever external funding round, led by Thrive Capital. That followed major research agreements signed the previous year with pharmaceutical giants Novartis and Eli Lilly. Under those partnerships, Isomorphic contributes to existing drug pipelines while also developing internal candidates in areas such as oncology and immunology. The aim is to license those compounds once early trial phases are complete. 'We identify an unmet need, and we start our own drug design programs,' Murdoch said. 'We develop those, put them into human clinical trials… we haven't got that yet, but we're making good progress.' Traditional drug development remains an expensive and risky process, with costs running into the millions and success rates in early trials often as low as 10%. > Isomorphic Labs is preparing to launch human trials of AI-designed drugs. > Mission: faster, cheaper, more accurate drug discovery using AI. AI will make the world a better place. One day, it might cure every disease and that future is got closer than we think. — AshutoshShrivastava (@ai_for_success) July 7, 2025 Murdoch believes Isomorphic's hybrid model, combining AI with pharma expertise, could radically improve those odds. 'We're trying to do all these things: speed them up, reduce the cost, but also really improve the chance that we can be successful,' he said. Murdoch envisions a future where AI models could generate effective drug designs at the click of a button. 'One day we hope to be able to say — well, here's a disease, and then click a button and out pops the design for a drug to address that disease,' he said. 'All powered by these amazing AI tools.'
Business Recorder
6 hours ago
- Business Recorder
Palm drops for a second session on weak rivals, crude oil
JAKARTA: Malaysian palm oil futures fell for a second straight session on Monday dragged by weaker rival edible oils and crude oil, while a weak ringgit lent some support. The benchmark palm oil contract for September delivery on the Bursa Malaysia Derivatives Exchange lost 15 ringgit, or 0.37%, to 4,047 ringgit ($956.06) a metric ton by the midday break. 'Bursa Malaysia crude palm oil futures opened marginally lower, mirroring spread adjustment against the competing vegetable oils,' a Kuala Lumpur-based trader said. Dalian's most-active soyoil contract dropped 1.05%, while its palm oil contract shed 0.42%. Soyoil prices on the Chicago Board of Trade plunged 1.76%. Palm oil tracks price movements of rival edible oils, as it competes for a share of the global vegetable oils market. Oil prices slipped on Monday after OPEC+ surprised markets by hiking output more than expected in August, raising concerns about oversupply. Weaker crude oil futures make palm a less attractive option for biodiesel feedstock. The ringgit, palm's currency of trade, weakened 0.36% against the dollar, making the commodity cheaper for buyers holding foreign currencies. Palm logs weekly gain despite weakness in rival oils, profit taking Malaysia's palm oil inventories likely dropped for the first time in four months in June as production fell unexpectedly while export demand remained robust for the tropical oil, a Reuters survey showed. Palm oil FCPOc3 may fall into the 4,008 ringgit to 4,032 ringgit per metric ton range, as a five-wave cycle from 3,947 ringgit has completed, Reuters technical analyst Wang Tao said.
